However, the study about the CSCs, especially the tumor cells with CD133 positivity, is still in the initial stage in GC, and the biological profiles of CSCs of gastric cancer should be further investigated in novel diagnosis, more suitable treatment strategies including the application of gene therapy by CD133 target and prognostic judgment in order to improve the effect of treatment on gastric cancer. The gene discussed is PROM1; the disease is neoplasm.